Novel triazole-quinoline derivatives as selective dual binding site acetylcholinesterase inhibitors

Molecules

Volumn 21, Issue 2, 2016, Pages

  Mantoani, Susimaire P ^a   Chierrito, Talita P C ^a   Vilela, Adriana F L ^a   Cardoso, Carmen L ^a   Martínez, Ana ^b   Carvalho, Ivone ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Click chemistry; Selective dual binding site inhibitors; Triazole quinoline derivatives

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; PROTEIN BINDING; QUINOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; CHEMISTRY; CLICK CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; KINETICS; MOLECULAR DOCKING;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; CLICK CHEMISTRY; HUMANS; KINETICS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; QUINOLINES; TRIAZOLES;

EID: 84963641679     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21020193     Document Type: Article

References (38)

1. Alonso, D.; Dorronsoro, I.; Rubio, L.; Munõz, P.; García-Palomero, E.; del Monte, M.; Bidon-Chanal, A.; Orozco, M.; Luque, F.J.; Castro, A.; et al. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg. Med. Chem. 2005, 13, 6588-6597. [CrossRef] [PubMed]
2. Kumar, A.; Singh, A. A review on Alzheimer's disease pathophysiology and its management: An update. Pharmacol. Rep. 2015, 67, 195-203. [CrossRef] [PubMed]
3. Colovic, M.B.; Krstic, D.Z.; Lazarevic-Pasti, T.D.; Bondzic, A.M.; Vasic, V.M. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr. Neuropharmacol. 2013, 11, 315-335. [CrossRef] [PubMed]
4. Hogan, D.B. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can. J. Psychiatry 2014, 59, 618-623. [PubMed]
5. Inestrosa, N.C.; Dinamarca, M.C.; Alvarez, A. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J. 2008, 275, 625-632. [CrossRef] [PubMed]
6. Castro, A.; Martinez, A. Peripheral and dual binding site acetylcholinesterase inhibitors: Implications in treatment of Alzheimer's disease. Mini Rev. Med. Chem. 2001, 1, 267-272. [CrossRef] [PubMed]
7. Castro, A.; Martinez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des. 2006, 12, 4377-4387. [CrossRef] [PubMed]
8. Camps, G.P.; Formosa, M.X.; Muñoz-Torrero, L.I.D.; Scarpellini, M. Acetylcholinesterase-Inhibiting Compounds for Treating Alzheimer Desease. WO 2007/122274 A1, 1 November 2007.
9. Camps, P.; Formosa, X.; Galdeano, C.; Gómez, T.; Muñoz-Torrero, D.; Scarpellini, M.; Viayna, E.; Badia, A.; Clos, M.V.; Camins, A.; et al. Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase-Induced-Amyloid Aggregation. J. Med. Chem. 2008, 51, 3588-3598. [CrossRef] [PubMed]
10. Camps, P.; Formosa, X.; Galdeano, C.; Gómez, T.; Muñoz-Torrero, D.; Ramírez, L.; Viayna, E.; Gómez, E.; Isambert, N.; Lavilla, R.; et al. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. Chem. Biol. Interact. 2010, 187, 411-415. [CrossRef] [PubMed]
11. Muñoz-Ruiz, P.; Rubio, L.; García-Palomero, E.; Dorronsoro, I.; del Monte-Mil, M.; Valenzuela, R.; Usán, P.; de Austria, C.; Bartolini, M.; Andrisano, V.; et al. Design, Synthesis, and Biological Evaluation of Dual Binding Site Acetylcholinesterase Inhibitors: New Disease-Modifying Agents for Alzheimer's Disease. J. Med. Chem. 2005, 48, 7223-7233. [CrossRef] [PubMed]
12. Luo, W.; Luo, W.; Li, Y.; He, Y.; Huang, S.; Tan, J.; Ou, T.; Li, D.; Gu, L.; Huang, Z. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation. Bioorg. Med. Chem. 2011, 19, 763-770. [CrossRef] [PubMed]
13. Shao, D.; Zou, C.; Luo, C.; Tang, X.; Li, Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg. Med. Chem. Lett. 2004, 14, 4639-4642. [CrossRef] [PubMed]
14. Korabecny, J.; Dolezal, R.; Cabelova, P.; Horova, A.; Hruba, E.; Ricny, J.; Sedlacek, L.; Nepovimova, E.; Spilovska, K.; Andrs, M.; et al. 7-MEOTAedonepezil like compounds as cholinesterase inhibitors: Synthesis, pharmacological evaluation, molecular modeling and QSAR Studies. Eur. J. Med. Chem. 2014, 82, 426-438. [CrossRef] [PubMed]
15. Hoffmann, G.R.; Deschênes, S.M.; Manyin, T.; Fuchs, R.P.P. Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli. Mutat. Res. 1996, 351, 33-43. [CrossRef]
16. Marella, A.; Tanwar, O.P.; Saha, R.; Ali, M.R.; Srivastava, S.; Akhter, M.; Shaquiquzzaman, M.; Alam, M.M. Quinoline: A versatile heterocyclic. Saudi Pharm. J. 2013, 21, 1-12. [CrossRef] [PubMed]
17. Hein, C.D.; Liu, X.M.;Wang, D. Click chemistry, a powerful tool for pharmaceutical sciences. Pharm. Res. 2008, 25, 2216-2230. [CrossRef] [PubMed]
18. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew. Chem. Int. Ed. 2001, 40, 2004-2021. [CrossRef]
19. Krasiński, A.; Radić, Z.; Manetsch, R.; Raushel, J.; Taylor, P.; Sharpless, K.B.; Kolb, H.C. In situ selection of lead compounds by click chemistry: Target-guided optimization of acetylcholinesterase inhibitors. J. Am. Chem. Soc. 2005, 127, 6686-6692. [CrossRef] [PubMed]
20. Shi, A.; Huang, L.; Lu, C.; He, F.; Li, X. Synthesis, biological evaluation and molecular modeling of novel triazole-containing berberine derivatives as acetylcholinesterase and β-amyloid aggregation inhibitors. Bioorg. Med. Chem. 2011, 19, 2298-2305. [CrossRef] [PubMed]
21. Mohammadi-Khanaposhtani, M.; Saeedi, M.; Zafarghandi, N.S.; Mahdavi, M.; Sabourian, R.; Razkenari, E.K.; Alinezhad, H.; Khanavi, M.; Foroumadi, A.; Shafiee, A.; et al. Potent acetylcholinesterase inhibitors: Design, synthesis, biological evaluation, and docking study of acridone linked to 1,2,3-triazole derivatives. Eur. J. Med. Chem. 2015, 92, 799-806. [CrossRef] [PubMed]
22. Silva, D.; Chioua, M.; Samadi, A.; Agostinho, P.; Garção, P.; Lajarín-Cuesta, R.; de los Ríos, C.; Iriepa, I.; Moraleda, I.; Gonzalez-Lafuente, L.; et al. Synthesis, Pharmacological Assessment, and Molecular Modeling of Acetylcholinesterase/Butyrylcholinesterase Inhibitors: Effect against Amyloid-β-Induced Neurotoxicity. ACS Chem. Neurosci. 2013, 4, 547-565. [CrossRef] [PubMed]
23. Williamson, R.T.; Marquez, B.L.; Gerwick, W.H.; Kövér, K. One- and two-dimensional gradient-selected HSQMBC NMR experiments for the efficient analysis of long-range heteronuclear coupling constants. Magn. Reson. Chem. 2000, 38, 265-273. [CrossRef]
24. CH heteronuclear coupling constants in cyclopentane derivatives. Magn. Reson. Chem. 2006, 44, 95-98. [CrossRef] [PubMed]
25. CH heteronuclear coupling constants in cyclopentane derivatives. Part II. Magn. Reson. Chem. 2007, 45, 82-86. [CrossRef] [PubMed]
26. CH dependence on dihedral angle. Magn. Reson. Chem. 2008, 46, 268-273. [CrossRef] [PubMed]
27. Mohrig, J.R.; Alberg, D.G.; Cartwright, C.H.; Pflum, M.K.; Aldrich, J.S.; Anderson, J.K.; Anderson, S.R.; Fimmen, R.L.; Snover, A.K. Stereochemistry of 1,2-elimination reactions at the E2-E1cB interface-tert-butyl 3-tosyloxybutanoate and its thioester. Org. Biomol. Chem. 2008, 6, 1641-1646. [CrossRef] [PubMed]
28. Ellman, G.L.; Courtney, K.D.; Andres, V., Jr.; Featherstone, M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88-95. [CrossRef]
29. Khorana, N.; Markmee, S.; Ingkaninan, K.; Ruchirawat, S.; Kitbunnadaj, R.; Pullagurla, M.R. Evaluation of a new lead for acetylcholinesterase inhibition. Med. Chem. Res. 2009, 18, 231-241. [CrossRef]
30. Rhee, I.K.; van Rijn, R.M.; Verpoorte, R. Qualitative determination of false-positive effects in the acetylcholinesterase assay using thin layer chromatography. Phytochem. Anal. 2003, 14, 127-131. [CrossRef] [PubMed]
31. Fang, J.;Wu, P.; Yang, R.; Gao, L.; Li, C.;Wang, D.;Wu, S.; Liu, A.L.; Du, G.H. Inhibition of acetylcholinesterase by two genistein derivatives: Kinetic analysis, molecular docking and molecular dynamics simulation. Acta Pharm. Sin. B 2014, 4, 430-437. [CrossRef] [PubMed]
32. Alhomida, A.S.; Al-Rajhi, A.A.; Kamal, M.A.; Al Jafari, A.A. Kinetic analysis of the toxicological effect of tacrine (Cognex®) on human retinal acetylcholinesterase activity. Toxicology 2000, 147, 33-39. [CrossRef]
33. Cheung, J.; Rudolph, M.J.; Burshteyn, F.; Cassidy, M.S.; Gary, E.N.; Love, J.; Franklin, M.C.; Height, J.J. Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands. J. Med. Chem. 2012, 55, 10282-10286. [CrossRef] [PubMed]
34. Jones, G.;Willett, P.; Glen, R.C.; Leach, A.R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748. [CrossRef] [PubMed]
35. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623. [CrossRef] [PubMed]
36. Liebeschuetz, J.W.; Cole, J.C.; Korb, O. Pose prediction and virtual screening performance of GOLD scoring functions in a standardized test. J. Comput. Aided Mol. Des. 2012, 26, 737-748. [CrossRef] [PubMed]
37. Armarego, W.L.F.; Chai, C.L.L. Purification of Laboratory Chemicals, 5th ed.; Butterworth-Heinemann: Amsterdam, The Netherlands, 2003.
38. García-Palomero, E.; Muñoz, P.; Usan, P.; Garcia, P.; Delgado, E.; de Austria, C.; Valenzuela, R.; Rubio, L.; Medina, M.; Martínez, A. Potent beta-amyloid modulators. Neurodegener. Dis. 2008, 5, 153-156. [CrossRef] [PubMed]